ZIMMER BIOMET HOLDINGS, INC. 4
4 · ZIMMER BIOMET HOLDINGS, INC. · Filed May 1, 2017
Insider Transaction Report
Form 4
DVORAK DAVID C
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2017-04-27$88.76/sh+100,000$8,876,000→ 381,886 total - Exercise/Conversion
Employee Stock Option (right to buy)
2017-04-27−100,000→ 0 totalExercise: $88.76Exp: 2017-04-30→ Common Stock (100,000 underlying) - Sale
Common Stock
2017-04-27$116.99/sh−34,547$4,041,654→ 294,555 total - Sale
Common Stock
2017-04-27$116.13/sh−52,784$6,129,806→ 329,102 total
Footnotes (5)
- [F1]Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
- [F2]Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
- [F3]Represents the sale of 52,784 shares in multiple transactions, ranging in price from $115.46 to $116.45 per share, resulting in a weighted average sale price of $116.13. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F4]Represents the sale of 34,547 shares in multiple transactions, ranging in price from $116.46 to $117.07 per share, resulting in a weighted average sale price of $116.99. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F5]Vested annually over four years in increments of 25% each year, commencing on May 1, 2008.